Cargando…
Pembrolizumab-Induced Lichen Planus: A Rare Immune-Related Adverse Side Effect
Pembrolizumab is the first anti-programmed death protein-1 agent approved by the US Food and Drug Administration. It has demonstrated efficacy in melanoma, lung cancer, and other advanced solid tumours and hematologic malignancies. Various dermatological side effects including pruritus, maculopapula...
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Wolters Kluwer - Medknow
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10231724/ https://www.ncbi.nlm.nih.gov/pubmed/37266094 http://dx.doi.org/10.4103/idoj.idoj_377_22 |